AEON BIOPHARMA INC (AEON)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.24-5.46%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AEON
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing ABP-450 through analytical similarity and seek FDA feedback on clinical pharmacology and comparative clinical study requirements.
Stated as a priority in 3 of last 3 quarters. Management reported progressing ABP-450 through analytical similarity phases and planned FDA BPD Type 2b meeting in second half of 2026 to define clinical study requirements. The trajectory shows delivering progress consistent with management's stated regulatory development focus.
“Primary focus is obtaining FDA feedback on next phase of development including clinical pharmacology and comparative clinical study requirements for ABP-450.”
“Plans to complete majority of analytical comparability program in 2026 and request BPD Type 2b meeting to discuss next phase of development.”
“Advancing ABP-450 as biosimilar to BOTOX with ongoing regulatory interactions and development.”
Raise capital through public offerings and financing transactions to improve cash runway and reduce outstanding debt.
Stated as a priority in 3 of last 3 quarters. The company completed financings raising $15.3M net proceeds in 2026-Q2 and earlier PIPE financing plus note exchange in 2026-Q1 reduced outstanding debt by over 90% from $34.6M to $1.5M. Cash and cash equivalents plus financing proceeds provide runway into early 2027. The trajectory is delivering significant balance sheet strengthening and liquidity improvement.
“Executed $15.3 million financing with milestone warrants providing cash runway into Q1 2027.”
“Completed PIPE financing and note exchange, strengthening balance sheet and reducing debt by over 90%.”
“Cash and cash equivalents expected to fund operations into Q3 2026 including recent financing.”
Regain and maintain compliance with NYSE American continued listing standards to avoid delisting risk.
Stated as a priority in 3 of last 3 quarters. The company received NYSE American non-compliance notices in 2025-Q4 and executed a plan including a July 2026 public offering that restored compliance by August 3, 2026. The trajectory shows delivering on the commitment to maintain listing compliance.
“Regained full compliance with NYSE American continued listing requirements on August 3, 2026.”
“Received notice of non-compliance with NYSE American listing standards and executing plan to regain compliance by August 3, 2026.”
“Company remains subject to NYSE American continued listing standards and working to regain compliance.”
Complete underwritten public offering with milestone warrants to raise capital for working capital and ABP-450 development.
Newly stated in 2026-Q2. The company completed an underwritten public offering raising approximately $13.6 million net proceeds with milestone warrants providing potential for an additional $34.0 million. This capital raise supports working capital and ABP-450 development. The trajectory shows execution of planned capital raise consistent with management statements.
“Completed underwritten public offering with net proceeds of approximately $13.6 million and milestone warrants for up to $34.0 million additional proceeds.”
“Pricing of upsized $13.75 million public offering with milestone warrants providing potential for additional $29.6 million in proceeds.”
Strengthen executive leadership by appointing experienced professionals to key roles.
Newly stated in 2026-Q1. The company appointed John Bencich as Chief Financial Officer to bolster leadership. No subsequent quarters restated this priority. The appointment represents a discrete talent strengthening event.
“Appointed John Bencich as Chief Financial Officer to strengthen executive leadership team.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 0.21x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.